olezarsen for familial chylylomicronaemia syndrome

Olezarsen is a next-generation, GalNAc3-conjugated antisense oligonucleotide that selectively targets hepatic apolipoprotein C-III (APOC-3) mRNA to reduce plasma triglyceride levels (1,2):

• National Institute for Health and Care Excellence (NICE) guidance TA1203 recommends olezarsen as an option for treating genetically confirmed familial chylomicronemia syndrome (FCS) in adults if response to diet and conventional triglyceride-lowering treatments (such as statins and fibrates) has been inadequate
• compared to the earlier ApoC-III antisense agent volanesorsen, olezarsen demonstrates similar clinical efficacy in triglyceride reduction while offering improved tolerability, fewer required injections, and avoiding the need for routine platelet monitoring

NICE Recommendations and Prescribing Criteria

NICE Indications (TA1203)

• recommended as an option for treating genetically confirmed familial chylomicronemia syndrome (FCS) in adults only if:
  • response to diet and conventional triglyceride-lowering therapies (e.g., statins, fibrates) is inadequate
  • the company provides olezarsen according to the agreed commercial arrangement
• NHS England commissioning: early funding is provided through the Innovative Medicines Fund (from 27 October 2026), transitioning to routine NHS commissioning

Clinical Positioning

• positioning in pathway: offered at the same treatment step as volanesorsen (following inadequate response to restricted low-fat diet and standard lipid-lowering agents)
• comparative advantage over volanesorsen: similar reduction in fasting triglyceride levels (~50% to 60%), but with superior tolerability, lower systemic antisense exposure, no requirement for weekly platelet monitoring, and lower overall treatment costs

Mechanism of Action and Efficacy

Targeted Antisense Mechanism

• selective APOC-3 inhibition: binds to hepatic APOC3 mRNA to trigger RNase H1-mediated cleavage, preventing ApoC-III protein translation
• dual clearance pathway: lowering ApoC-III releases the inhibition on lipoprotein lipase (LPL) and promotes LPL-independent hepatic clearance of triglyceride-rich lipoproteins (TRLs), effectively lowering triglycerides even in patients with defective LPL enzyme activity

Clinical Evidence

• fasting triglyceride reduction: Phase 3 trial data (BALANCE) show that once-monthly olezarsen 80 mg reduces fasting triglycerides by approximately 44% at 6 months and 59% at 12 months in patients with FCS
• pancreatitis risk reduction: significantly reduces the incidence of acute pancreatitis compared to placebo in patients with severe hypertriglyceridemia

Dosing, Administration, and Safety

Administration Regimen

• formulation and route: pre-filled pen administered as an 80 mg subcutaneous injection once monthly
• monitoring requirements: unlike volanesorsen, routine weekly platelet monitoring is not required due to GalNAc3 hepatocyte-targeting chemistry

Safety Profile

• common adverse effects: predominantly mild injection-site reactions (redness, pain, swelling) and arthralgia
• hematological safety: no severe thrombocytopenia (platelets <50,000/microlitre) observed in clinical trials

Reference:

1. National Institute for Health and Care Excellence (NICE). Olezarsen for treating familial chylomicronemia syndrome. NICE Technology Appraisal Guidance [TA1203]. Published 27 October 2026.
2. Joshy J, Javed A, Singh MK, et al. Olezarsen: A Next-Generation Antisense Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome. Cureus. 2025;17(11):e96715.